Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Bird Rock Bio, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03900325
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸PRN of Kansas, Wichita, Kansas, United States
🇺🇸Panax Clinical Research, Miami, Florida, United States
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Phase 1
Completed
- Conditions
- NAFLD
- Interventions
- Biological: PlaceboBiological: RYI-018
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Bird Rock Bio, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT03261739
- Locations
- 🇨🇦
BRB Site, Toronto, Ontario, Canada
Study Evaluating Gerilimzumab´s Safety/Efficacy for Patients MTX or TNFα Antagonist Failed in Rheumatoid Arthritis
Phase 2
Withdrawn
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Bird Rock Bio, Inc.
- Registration Number
- NCT02795299
© Copyright 2025. All Rights Reserved by MedPath